Pulse Biosciences nPulse catheter posts 96% AF ablation success at one year

Pulse Biosciences, Inc.

Pulse Biosciences, Inc.

PLSE

0.00
  • Pulse Biosciences reported updated first-in-human feasibility study results for nPulse cardiac catheter system using nanosecond pulsed field ablation at Heart Rhythm 2026.
  • Data were presented April 25 as a late-breaking update, expanding follow-up cohorts to 95 patients at 6 months and 53 patients at 12 months.
  • Study showed sustained rhythm-control durability with high procedural success through 1 year, supporting competitive positioning in atrial fibrillation ablation.
  • Outcomes also pointed to an efficient workflow with short procedure times, which could lower lab utilization and improve adoption economics.
  • Safety profile remained favorable with low serious adverse events across 177 treated patients, reducing a key commercialization risk for the device program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulse Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604251300BIZWIRE_USPR_____20260425_BW875774) on April 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.